Paladin Labs Inc., the Montreal-based Canadian distributor of the abortifacient morning-after pill.
Plan B, announced that it has submitted an application to Health Canada to change Plan B, from prescription-only to non-prescription status. A Paladin press release noted that the Canadian Pharmacists Association and the Society of Obstetricians and Gynecologists of Canada collaberated on the submission.
Campaign Life Coalition urged Health Canada to reject the application, noting that the morning after pill “acts upon the uterine lining to make it hostile to the implantation of the human embryo. This would be analogous to leaving a newborn baby alone in the desert and is clearly an abortificient action.”
